Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/ΔFosB–VCAM-1 axis

A thermostable drug suppresses a pERK-FosB/ΔFosB-VCAM-1 axis, endothelial activation, angiogenesis, and retinal permeability. Vascular permeability and angiogenesis underpin neovascular age-related macular degeneration and diabetic retinopathy. While anti-VEGF therapies are widely used clinically, many patients do not respond optimally, or at all, and small-molecule therapies are lacking. Here, we identified a dibenzoxazepinone BT2 that inhibits endothelial cell proliferation, migration, wound repair in vitro, network formation, and angiogenesis in mice bearing Matrigel plugs. BT2 interacts with MEK1 and inhibits ERK phosphorylation and the expression of FosB/ΔFosB, VCAM-1, and many genes involved in proliferation, migration, angiogenesis, and inflammation. BT2 reduced retinal vascular leakage following rat choroidal laser trauma and rabbit intravitreal VEGF-A165 administration. BT2 suppressed retinal CD31, pERK, VCAM-1, and VEGF-A165 expression. BT2 reduced retinal leakage in rats at least as effectively as aflibercept, a first-line therapy for nAMD/DR. BT2 withstands boiling or autoclaving and several months’ storage at 22°C. BT2 is a new small-molecule inhibitor of vascular permeability and angiogenesis.

[1]  Ahmad M. N. Alhendi,et al.  Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/ΔFosB-VCAM-1 axis. , 2020, Science advances.

[2]  J. Leem,et al.  Protective Effects of Melatonin Against Aristolochic Acid-Induced Nephropathy in Mice , 2019, Biomolecules.

[3]  N. Ferrara,et al.  VEGF in Signaling and Disease: Beyond Discovery and Development , 2019, Cell.

[4]  A. Oishi,et al.  Plasma markers of chronic low‐grade inflammation in polypoidal choroidal vasculopathy and neovascular age‐related macular degeneration , 2018, Acta ophthalmologica.

[5]  Tao Yan,et al.  EGFR inhibitor, AG1478, inhibits inflammatory infiltration and angiogenesis in mice with diabetic retinopathy , 2018, Clinical and experimental pharmacology & physiology.

[6]  P. Mitchell,et al.  Age-related macular degeneration , 2018, The Lancet.

[7]  A. Elshaer,et al.  The use of albumin solid dispersion to enhance the solubility of unionizable drugs , 2018, Pharmaceutical development and technology.

[8]  M. Salvati,et al.  Oral Delivery of Highly Lipophilic, Poorly Water-Soluble Drugs: Self-Emulsifying Drug Delivery Systems to Improve Oral Absorption and Enable High-Dose Toxicology Studies of a Cholesteryl Ester Transfer Protein Inhibitor in Preclinical Species. , 2018, Journal of pharmaceutical sciences.

[9]  Geet Duggal,et al.  Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference , 2017, Nature Methods.

[10]  Rob Patro,et al.  Salmon provides fast and bias-aware quantification of transcript expression , 2017, Nature Methods.

[11]  Jayme L. Dahlin,et al.  The Essential Medicinal Chemistry of Curcumin , 2017, Journal of medicinal chemistry.

[12]  A. Ho,et al.  Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. , 2016, American journal of ophthalmology.

[13]  Glenn J Jaffe,et al.  Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. , 2016, Ophthalmology.

[14]  T. Hong,et al.  Diabetic macular oedema: pathophysiology, management challenges and treatment resistance , 2016, Diabetologia.

[15]  Dezheng Zhao,et al.  AP-1 transcription factor mediates VEGF-induced endothelial cell migration and proliferation. , 2016, Microvascular research.

[16]  F. Falcão-Reis,et al.  Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes , 2016, Clinical ophthalmology.

[17]  X. Qin,et al.  Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma , 2016, Scientific Reports.

[18]  S. Kyosseva.  Targeting MAPK Signaling in Age-Related Macular Degeneration , 2016, Ophthalmology and eye diseases.

[19]  M. Mishra,et al.  Molecular Mechanism of Transcriptional Regulation of Matrix Metalloproteinase‐9 in Diabetic Retinopathy , 2016, Journal of cellular physiology.

[20]  M. Raizada,et al.  Activation of endogenous angiotensin converting enzyme 2 prevents early injuries induced by hyperglycemia in rat retina , 2015, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[21]  Martin Friedlander,et al.  Neurovascular crosstalk between interneurons and capillaries is required for vision. , 2015, The Journal of clinical investigation.

[22]  L. Chu,et al.  Study of 27 Aqueous Humor Cytokines in Type 2 Diabetic Patients with or without Macular Edema , 2015, PloS one.

[23]  E. Nestler.  ∆FosB: a transcriptional regulator of stress and antidepressant responses. , 2015, European journal of pharmacology.

[24]  Jennifer K. Sun,et al.  Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. , 2015, The New England journal of medicine.

[25]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[26]  Giovanni Staurenghi,et al.  Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration , 2014, British Journal of Ophthalmology.

[27]  Nicholas A. Popp,et al.  Animal models of age-related macular degeneration and their translatability into the clinic , 2014, Expert review of ophthalmology.

[28]  Na Ye,et al.  Small Molecule Inhibitors Targeting Activator Protein 1 (AP-1) , 2014, Journal of medicinal chemistry.

[29]  T. Oshitari,et al.  Increased Expression of c-Fos, c-Jun and c-Jun N-Terminal Kinase Associated with Neuronal Cell Death in Retinas of Diabetic Patients , 2014, Current eye research.

[30]  Kang Zhang,et al.  Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). , 2013, Ophthalmology.

[31]  R. Schlingemann,et al.  Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions , 2013, Progress in Retinal and Eye Research.

[32]  P. Campochiaro.  Ocular neovascularization , 2013, Journal of Molecular Medicine.

[33]  M. Pennesi,et al.  Animal models of age related macular degeneration. , 2012, Molecular aspects of medicine.

[34]  C. Bruyns,et al.  Characterization of retinal expression of vascular cell adhesion molecule (VCAM-1) during experimental autoimmune uveitis. , 2012, Experimental eye research.

[35]  T. Wong,et al.  Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals , 2012, Disease Models & Mechanisms.

[36]  Gezhi Xu,et al.  ERK1/2 signaling pathway in the release of VEGF from Müller cells in diabetes. , 2012, Investigative ophthalmology & visual science.

[37]  Brad T. Sherman,et al.  DAVID-WS: a stateful web service to facilitate gene/protein list analysis , 2012, Bioinform..

[38]  U. Kompella,et al.  Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. , 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[39]  J. Jonas,et al.  Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration. , 2010, Archives of ophthalmology.

[40]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[41]  H. Kleinman,et al.  The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art , 2009, Angiogenesis.

[42]  R. Adelman,et al.  Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[43]  G. Lizard,et al.  Adhesion molecules (ICAM-1 and VCAM-1) and diabetic retinopathy in type 2 diabetes , 2008, Journal of Molecular Histology.

[44]  M. Slevin,et al.  Cheiradone: a vascular endothelial cell growth factor receptor antagonist , 2008, BMC Cell Biology.

[45]  M. Humayun,et al.  The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. , 2007, Investigative ophthalmology & visual science.

[46]  P. Campochiaro,et al.  TNF-α is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage , 2007, Journal of Neuroimmunology.

[47]  C. Fan,et al.  Interactions between Endostatin and Vascular Endothelial Growth Factor (VEGF) and Inhibition of Choroidal Neovascularization , 2007, International Journal of Molecular Sciences.

[48]  E. Turner,et al.  Interleukin-1β induced vascular permeability is dependent on induction of endothelial Tissue Factor (TF) activity , 2005, Journal of Translational Medicine.

[49]  A. Caicedo,et al.  Blood-derived macrophages infiltrate the retina and activate Muller glial cells under experimental choroidal neovascularization. , 2005, Experimental eye research.

[50]  K. Ohtsuka,et al.  Activator protein-1 in epiretinal membranes of patients with proliferative diabetic retinopathy , 2005, Diabetologia.

[51]  P. Angel,et al.  AP-1 subunits: quarrel and harmony among siblings , 2004, Journal of Cell Science.

[52]  R. Shao,et al.  Human microvascular endothelial cells immortalized with human telomerase catalytic protein: a model for the study of in vitro angiogenesis. , 2004, Biochemical and biophysical research communications.

[53]  S. Hayreh,et al.  Ocular neovascularization , 1980, International Ophthalmology.

[54]  A. Yoshida,et al.  Extracellular signal-regulated kinase activation predominantly in Müller cells of retina with endotoxin-induced uveitis. , 2002, Investigative ophthalmology & visual science.

[55]  D. Gingras,et al.  Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. , 2002, Cancer research.

[56]  T. Sano,et al.  [Diabetic retinopathy]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[57]  V. Reppucci,et al.  Soluble cellular adhesion molecules in proliferative vitreoretinopathy and proliferative diabetic retinopathy. , 1999, Current eye research.

[58]  A. Albini,et al.  c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[59]  W. Risau,et al.  Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. , 1997, The Biochemical journal.

[60]  A. Bridges,et al.  A synthetic inhibitor of the mitogen-activated protein kinase cascade. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[61]  F. Jones.  THE EFFECT OF HEAT ON ANTIBODIES , 1927, The Journal of experimental medicine.